Clinical Sciences. Prediction of Cardioembolic, Arterial, and Lacunar Causes of Cryptogenic Stroke by Gene Expression and Infarct Location
|
|
- Patrick Short
- 5 years ago
- Views:
Transcription
1 Clinical Sciences Prediction of Cardioembolic, Arterial, and Lacunar Causes of Cryptogenic Stroke by Gene Expression and Infarct Location Glen C. Jickling, MD, MAS; Boryana Stamova, PhD; Bradley P. Ander, PhD; Xinhua Zhan, MD, PhD; Dazhi Liu, PhD; Shara-Mae Sison, BS; Piero Verro, MD; Frank R Sharp, MD Background and Purpose The cause of ischemic stroke remains unclear, or cryptogenic, in as many as 35% of patients with stroke. Not knowing the cause of stroke restricts optimal implementation of prevention therapy and limits stroke research. We demonstrate how gene expression profiles in blood can be used in conjunction with a measure of infarct location on neuroimaging to predict a probable cause in cryptogenic stroke. Methods The cause of cryptogenic stroke was predicted using previously described profiles of differentially expressed genes characteristic of patients with cardioembolic, arterial, and lacunar stroke. RNA was isolated from peripheral blood of 131 cryptogenic strokes and compared with profiles derived from 149 strokes of known cause. Each sample was run on Affymetrix U133 Plus 2.0 microarrays. Cause of cryptogenic stroke was predicted using gene expression in blood and infarct location. Results Cryptogenic strokes were predicted to be 58% cardioembolic, 18% arterial, 12% lacunar, and 12% unclear etiology. Cryptogenic stroke of predicted cardioembolic etiology had more prior myocardial infarction and higher CHA 2 DS 2 -VASc scores compared with stroke of predicted arterial etiology. Predicted lacunar strokes had higher systolic and diastolic blood pressures and lower National Institutes of Health Stroke Scale compared with predicted arterial and cardioembolic strokes. Cryptogenic strokes of unclear predicted etiology were less likely to have a prior transient ischemic attack or ischemic stroke. Conclusions Gene expression in conjunction with a measure of infarct location can predict a probable cause in cryptogenic strokes. Predicted groups require further evaluation to determine whether relevant clinical, imaging, or therapeutic differences exist for each group. (Stroke. 2012;43: ) Key Words: cryptogenic stroke diagnosis gene expression ischemic stroke The cause of stroke remains unclear, or cryptogenic, in as many as 35% of ischemic strokes despite careful clinical evaluation and diagnostic imaging. 1,2 This corresponds to cryptogenic strokes per year (32 per hour) in the United States alone. Knowing the cause of stroke is essential to optimally implement prevention therapy. Given the 2-year mortality rate of cryptogenic strokes is 39%, there remains a significant need to prevent cardiovascular disease in this subtype of stroke. 3 Accurate determination of stroke cause is also an important component in patient prognosis and in studies of stroke epidemiology, genetics, and therapeutics. Thus, additional approaches to determine the cause of cryptogenic strokes are required. When predicting the cause of cryptogenic stroke, stratification by infarct location can aid prediction. Cryptogenic small deep infarcts (SDIs) occurring in the regions of the penetrating arteries require lacunar, arterial, and cardiac disease all to be considered as a potential cause of stroke. 4 However, in cryptogenic non-sdis, only arterial and cardiac disease need to be considered as a potential cause of stroke. Other less common causes may contribute to either of these groups. Thus, infarct location can reduce the number of potential causes of stroke that need to be considered in the non-sdi group, which simplifies prediction models of cryptogenic stroke cause. We recently described a gene expression profile to distinguish cardioembolic from arterial stroke and a separate gene expression profile to distinguish lacunar from nonlacunar stroke. 4,5 In patients with cryptogenic stroke, these profiles may predict a probable cause to guide diagnostic and therapeutic studies. The profiles are based on differential inflammatory and prothrombotic states present in subtypes of stroke. In this study, we describe the integration of the 2 gene expression profiles with a measure of infarct location on Received December 20, 2011; accepted April 10, From the Department of Neurology and MIND Institute, University of California at Davis, Sacramento, CA. The online-only Data Supplement is available at Correspondence to Glen C. Jickling, MD, MAS, University of California at Davis, MIND Institute, th Street, Sacramento, CA gcjickling@ucdavis.edu 2012 American Heart Association, Inc. Stroke is available at DOI: /STROKEAHA
2 Jickling et al Cryptogenic Stroke Prediction 2037 Figure 1. Flow diagram for the prediction of cryptogenic stroke by infarct location and gene expression profiles. Cryptogenic strokes were divided into small deep infarcts (SDIs) and non- SDIs by location of infarct on neuroimaging. Cryptogenic SDIs were predicted to be lacunar or nonlacunar stroke using a 41-gene profile. SDIs of predicted nonlacunar stroke were then predicted to be arterial or cardioembolic stroke using a 40-gene profile. Cryptogenic non-sdis were predicted to be arterial or cardioembolic stroke using the 40-gene profile. neuroimaging to predict the probable cause of cryptogenic stroke. Methods Study Patients Patients with acute ischemic stroke were enrolled from the University of California Davis and as part of the Combined Approach to Lysis Utilizing Eptifibatide and rtpa in Acute Ischemic Stroke (CLEAR) trial at the University of Cincinnati as previously described 6 (NCT at Clinical-Trials.gov). The Institutional Review Board at each site approved the study protocol and written informed consent was obtained from each patient. Patients with ischemic stroke were 18 years of age, had acute ischemia on neuroimaging, and new neurological deficits persisting 24 hours. All patients had standardized clinical evaluations. Blood samples were drawn into PAXgene tubes (PreAnalytiX, Hilden, Germany) within 72 hours of stroke onset. A total of 131 cryptogenic stroke samples were analyzed using gene expression profiles derived from 149 strokes of known cause (79 cardioembolic, 40 arterial, 30 lacunar). The cause of stroke was determined by 2 board-certified stroke neurologists based on medical history, blood tests, neuroimaging, Doppler, vascular angiography, electrocardiography, echocardiogram, and 24- to 48-hour cardiac monitoring. Strokes of arterial, cardioembolic, and lacunar etiology that were used to derive the expression profiles have been previously described. 4,5 In brief, arterial strokes were patients with stenosis 50% in an intracranial or extracranial vessel referable to the infarct without other cause of stroke. Cardioembolic stokes included patients with atrial fibrillation, acute myocardial infarction, valvular heart disease, or marked ventricular hypokinesis without other cause of stroke. Patients with atrial myxoma or endocarditis were excluded. Lacunar strokes had a lacunar syndrome with a corresponding infarct 15 mm in largest diameter in a region of the penetrating arteries without other cause of stroke. Cryptogenic strokes were patients with no determined etiology despite extensive evaluation or patients with 2 potential causes of stroke so that a final diagnosis was not possible. Strokes with incomplete evaluation were excluded from study. Cryptogenic strokes were divided based on infarct location into 2 groups, SDI and non-sdi (Figure 1). Infarct location was identified by restricted diffusion on MRI or hypodensity on CT. Subjects without imaging evidence of infarction were excluded from study. Cryptogenic SDI had strokes in the regions of the penetrating arteries with infarcts 15 mm in diameter and/or 2 potential causes of stroke. Regions of the penetrating arteries included the basal ganglia, internal capsule, thalamus, corona radiata, and pons. Cryptogenic non-sdis were strokes not in the regions of the penetrating arteries (mainly cortical), in which lacunar stroke would not be considered a cause of stroke. Sample Processing Blood was collected by venipuncture into PAXgene tubes (Pre- AnalytiX). Samples were stored frozen and then processed at the same time to minimize technical variation. Total RNA was isolated according to protocol (PAXgene blood RNA kit; Pre-AnalytiX) and analyzed for quality using Agilent 2100 Bioanalyzer and quantity by Nano-drop. Reverse transcription, amplification, and sample labeling were carried out using Nugen s Ovation Whole Blood reagents (Nugen Technologies, San Carlos, CA). Each RNA sample was hybridized to Affymetrix Genome U133 Plus 2 GeneChips and scanned according to protocol (Affymetrix, Santa Clara, CA). Raw expression values were preprocessed using robust multichip averaging, mean-centering standardization, and log 2 transformation for prediction analyses (Partek Genomics Suite 6.4; Partek Inc, St Louis, MO). Gene Profiles The profiles used to predict cause in cryptogenic stroke have been described previously. A 41-gene list was identified to distinguish patients with lacunar stroke from nonlacunar stroke 5 (online-only Data Supplement Table I). In addition, a 40-gene list was identified to distinguish patients with cardioembolic stroke from patients with arterial stroke 4 (Figure 1; online-only Data Supplement Table II). These gene profiles were derived from patients with known cardioembolic, arterial, and lacunar causes of stroke. Prediction of Cryptogenic Stroke Prediction analyses were performed using linear discriminant analysis (Partek Genomics Suite 6.4) and nearest shrunken centroid (Prediction Analysis of Microarrays) algorithms and principal components analysis (Partek Genomics Suite 6.4; Figure 2). 7 Patients with known cause of stroke were used to develop prediction models to distinguish cardioembolic from arterial causes of stroke 4 and to distinguish lacunar from nonlacunar causes of stroke. 5 These models were applied to groups of patients with cryptogenic stroke to predict the cause of stroke (Figure 1). The prediction models assign a probability of belonging to a type of stroke based on the pattern of gene expression. For example, cryptogenic strokes with a pattern of gene expression similar to patients with known cardioembolic stroke are predicted to be cardioembolic stroke. This prediction is performed to determine which cryptogenic strokes are most likely cardioembolic, arterial, or lacunar. Prediction of cryptogenic strokes was performed using gene expression in conjunction with infarct location. Cryptogenic SDIs in regions of the penetrating arteries were first predicted to be of either lacunar or nonlacunar etiology using the 41-gene profile (Figure 1; online-only Data (Supplement Table I). Cryptogenic SDIs of predicted nonlacunar etiology were then predicted to be of cardioembolic or arterial etiology using the 40-gene profile. Cryptogenic non-sdis (mostly cortical infarcts) were predicted to be of cardioembolic or arterial etiology using the 40-gene profile (online-only Data Supplement Table II). The 41-gene profile was not used to predict this group because lacunar stroke is not a consideration in patients with non-sdi. A predicted diagnosis of stroke cause required an average predicted probability of 75%. Subjects not meeting these criteria remained of unclear cause. Statistical Analyses Differences in demographic and clinical data between predicted stroke groups were analyzed using 2 or Fisher exact test, Kruskal-Wallis, or analysis of variance as appropriate (Stata 10.1, College Station, TX). Data are presented as mean SD for continuous variables and median with interquartile range for ordinal variables.
3 2038 Stroke August 2012 Figure 2. Principal components analysis (PCA) of cryptogenic strokes using the genes predictive of stroke cause. A, PCA of non-sdi cryptogenic strokes predicted to be arterial or cardioembolic stroke using the 40-gene profile. B, PCA of SDI cryptogenic strokes predicted to be lacunar or nonlacunar stroke using the 41-gene profile. C, PCA of the cryptogenic SDI predicted to be nonlacunar stroke in B, predicted to be arterial or cardioembolic stroke using the 40-gene profile. SDI indicates small deep infarct. Results Cryptogenic Strokes The demographic and clinical features of the 131 patients with cryptogenic stroke are summarized in Table 1. The average age was 63.9 years (SD 14.8) and 54.2% were male. Cryptogenic strokes were of diverse race and ethnicity with 74% white, 16% black, 6.1% Hispanic, and 3.9% of other race. Hypertension was present in 62.6%, hyperlipidemia in 25.2%, and diabetes in 18.3%. 21.4% had prior stroke or transient ischemic attack, 15.3% had prior myocardial infarction, and 3.1% had atrial fibrillation. The median National Institutes of Health Stroke Scale on admission was 10.6 (interquartile range, ). There were 32 (24.4%) SDI and 99 (75.6%) non-sdi. The demographics of the patients with cryptogenic stroke were similar to strokes of known etiology used to derive the gene expression profiles. The Table 1. Characteristics of the 131 Cryptogenic Stroke Subjects Studied Characteristic Value Age, y (SD) 63.9 (14.8) Male, no. (%) 71 (54.2%) Hypertension, no. (%) 82 (62.6%) Systolic BP, mm Hg (SD) (36.0) Diastolic BP, mm Hg (SD) 86.8 (18.7) Diabetes, no. (%) 24 (18.3%) Body mass index, kg/m 2 (SD) 28.7 (4.5) Hyperlipidemia, no. (%) 33 (25.2%) Current smoking, no. (%) 44 (33.6%) Atrial fibrillation, no. (%) 4 (3.1%) Prior myocardial infarction, no. (%) 20 (15.3%) Congestive heart failure, no. (%) 6 (4.6%) Prior stroke or TIA, no. (%) 28 (21.4%) NIHSS on admission (IQR) 10.6 (6 16) BP indicates blood pressure; TIA, transient ischemic attack; NIHSS, National Institutes of Health Stroke Scale; IQR, interquartile range. average age for strokes of known etiology was 67.7 years (SD 10.4), 59.1% were male, 73.2% had hypertension, 31.5% had hyperlipidemia, and 30.2% had diabetes (online-only Data Supplement Table III). Cryptogenic Stroke Predicted by Gene Expression and Infarct Location Of the 32 SDI cryptogenic strokes, 11 (34.4%) were predicted to be cardioembolic, 4 (12.5%) to be arterial, 15 (46.9%) to be lacunar, and 2 (6.3%) remained of unclear etiology. Of the 99 non-sdi cryptogenic strokes, 65 (65.7%) were predicted to be cardioembolic, 20 (20.2%) to be arterial, and 14 (14.1%) remained of unclear etiology. Thus, when combined, the 131 cryptogenic strokes resulted in 76 (58.0%) subjects predicted to be cardioembolic, 24 (18.3%) to be arterial, and 15 (11.5%) to be lacunar (Figure 1). There remained 16 (12.2%) subjects in which the diagnostic probability was insufficient to assign a predicted class. Separation of cryptogenic stroke into predicted causes by gene expression profiles is shown by principal components analysis in Figure 2 (Partek Genomics Suite 6.4). 7 The characteristics of cryptogenic strokes divided by predicted etiology is shown in Table 2. Groups were similar in gender, hypertension, diabetes, and hyperlipidemia. Cryptogenic strokes of predicted cardioembolic etiology had more prior myocardial infarction and higher CHA 2 DS 2 -VASc scores compared with cryptogenic strokes of predicted arterial etiology. Cryptogenic strokes of predicted lacunar etiology had higher systolic and diastolic blood pressures and a lower National Institutes of Health Stroke Scale compared with cryptogenic strokes predicted to be arterial or cardioembolic. Cryptogenic strokes that remained of unclear etiology had less history of stroke or transient ischemic attack. Discussion We describe the use of RNA expression profiles in blood in conjunction with infarct location to identify probable cardioembolic, arterial, and lacunar causes of cryptogenic stroke. The predicted causes of cryptogenic stroke require further
4 Jickling et al Cryptogenic Stroke Prediction 2039 Table 2. Characteristics of Cryptogenic Strokes Divided by Their Predicted Etiology Based on Gene Expression Profiles and Infarct Location Cardioembolic (n 76) Arterial (n 24) Lacunar (n 15) Unclear (n 16) P Value Age, y (SD) 65.2 (16.5) 61.1 (11.5) 62.9 (13.7) 61.1 (11.5) 0.05 Male, no. (%) 35 (46.1%) 15 (62.5%) 9 (60.0%) 12 (75.0%) 0.13 Hypertension, no. (%) 46 (60.6%) 17 (70.8%) 12 (80.0%) 7 (43.8%) 0.1 Systolic BP, mm Hg (SD) (37.9) (38.1) (37.3) (17.6) 0.05 Diastolic BP, mm Hg (SD) 85.5 (16.9) 81.0 (21.2) 97.9 (21.3) 90.1 (17.6) 0.05 Diabetes, no. (%) 12 (15.8%) 6 (25.0%) 5 (33.3%) 1 (6.3%) 0.15 Body mass index, kg/m 2 (SD) 28.5 (3.9) 29.0 (2.7) 28.4 (5.1) 31.6 (9.3) 0.61 Hyperlipidemia, no. (%) 19 (25.0%) 4 (16.7%) 6 (40%) 4 (25.0%) 0.35 Current smoking, no. (%) 21 (27.6%) 10 (41.7%) 6 (40.0%) 7 (43.8%) 0.58 Atrial fibrillation, no. (%) 3 (3.9%) 0 1 (6.7%) Prior myocardial infarction, no. (%) 17 (22.4%) (18.8%) 0.02 Congestive heart failure, no. (%) 6 (7.9%) CHA 2 DS 2 -VASc (IQR) 3.1 (2 4) 2.0 (1 2.7) 2.8 ( ) 1.6 (0 3) 0.05 Prior stroke or TIA, no. (%) 21 (27.6%) 3 (12.5%) 4 (26.7%) NIHSS on admission (IQR) 9.6 (6 11.5) 12.1 (6 19) 3.3 (2 3.5) 16.6 (12 23) 0.05 Cryptogenic strokes were predicted to be of cardioembolic, arterial, or lacunar etiology. Strokes of unclear predicted cause were subjects in which the diagnostic probability was insufficient to assign a predicted class. BP indicates blood pressure; IQR, interquartile range; TIA, transient ischemic attack; NIHSS, National Institutes of Health Stroke Scale. study to determine whether relevant epidemiological or therapeutic differences exist for each group. The described approach to determine a probable cause of cryptogenic stroke represents an important step to better classify a patient group that accounts for as many as one third of ischemic strokes. Cardioembolic stroke was the predicted cause in 58% of cryptogenic strokes studied. This is consistent with previous studies indicating cardioembolism is a contributor to cryptogenic stroke Indeed, paroxysmal atrial fibrillation not detected on initial investigations can later be identified in 10% to 25% of cryptogenic strokes with prolonged cardiac monitoring. 8,11 In our study, a higher CHA 2 DS 2 -VASc score in predicted cardioembolic subjects may support the presence of undetected paroxysmal atrial fibrillation. This requires further evaluation by prolonged cardiac recording. Patent foramen ovale may also contribute to cryptogenic stroke, although this remains controversial The prevalence of patent foramen ovale is increased in cryptogenic strokes compared with control subjects, 15,16 and trials of patent foramen ovale closure in cryptogenic stroke are ongoing. 17 Whether cryptogenic strokes of predicted cardioembolic etiology may derive greater benefit from patent foramen ovale closure may be of interest for future evaluation. Prior myocardial infarction was also identified to be more common in cryptogenic strokes of predicted cardioembolic etiology. Although the significance of this remains unclear, a prior myocardial infarction in cryptogenic stroke may be an indicator of underlying cardiac disease associated with stroke. Arterial disease was a predicted cause of cryptogenic stroke in 18.3% of subjects. Prior studies also suggest that arterial disease likely contributes to cryptogenic stroke, including arterial stenosis 50%, plaque ulceration, intracranial atherosclerosis, and aortic plaque. 10,18,19 Indeed, arterial stenosis 50% and the presence of arterial plaque are both considered in the Causative Classification for Ischemic Stroke and the Atherosclerosis, Small Vessel Disease, Cardiac Source, Other Cause (A-S-C-O) classification systems as features that increase the probability of arterial stroke. 20,21 Ulcerated plaques missed by current investigations may also account for some of the predicted arterial cryptogenic strokes, particularly given that two thirds of ulcerated carotid arteries occur with stenoses of 0% to 49%. 22 Further evaluation to determine whether such features are more common in cryptogenic strokes of predicted arterial etiology is required. Lacunar stroke was a predicted cause of cryptogenic stroke in 11.5% of subjects. Lacunar stroke differs from arterial and cardioembolic stroke in that the source of stroke is inferred by infarct size and location rather than directly identified. Thus, lacunar stroke is only a consideration when an infarct is located in the region of the penetrating arteries. These small deep infarcts are cryptogenic when an arterial and/or cardioembolic source of stroke is present or when the infarct is 15 mm in diameter. The prediction of cause by gene expression suggests that some small deep infarcts 15 mm in size, or with a coincidental arterial or cardiac source of stroke, are lacunar strokes. Evaluating these predicted causes will require follow-up. Subjects of predicted lacunar etiology would be expected to be more likely to have recurrent lacunar infarcts, whereas SDIs of predicted arterial or cardioembolic etiology would be expected to have recurrent infarcts in regions not supplied by deep penetrating arteries. In this study, 76% of cryptogenic strokes were predicted to be of either arterial or cardioembolic etiology. This is consistent with previous epidemiological studies indicating cryptogenic strokes have a long-term prognosis similar to that of arterial and cardioembolic stroke. The 2-year survival rate
5 2040 Stroke August 2012 of cryptogenic stroke is 61%, which is closer to the survival rate of cardioembolic stroke at 55% and arterial stroke at 58% compared with lacunar stroke at 85%. 3 Additionally, cryptogenic strokes are more likely to have recurrent arterial or cardioembolic strokes. 23 Finally, outcome in cryptogenic stroke is closer to that of cardioembolic and arterial stroke than lacunar stroke. At 90 days, 35.8% of cryptogenic strokes have a modified Rankin Scale score 3, 24 compared with 56.8% of cardioembolic strokes, 32.4% of arterial strokes, and only 4.2% of lacunar strokes. 24 The Causative Classification for Ischemic Stroke and A-S-C-O classification systems demonstrate how additional clinical and imaging features can be used to further characterize stroke subtype. Likewise, genetic data may also provide additional information to characterize stroke subtype. We demonstrate how RNA expression profiles can predict a likely cause in cryptogenic stroke. A gene expression profile could be developed into a clinical assay similar to those developed for breast cancer and coronary artery disease. 25,26 The RNA results would provide an indication of whether a patient is likely of arterial, cardioembolic, or lacunar etiology, which could be interpreted along with other diagnostic information to determine stroke cause. This discovery type study has limitations. Although echocardiography was performed in all subjects, transesophageal echocardiography was not. Contrast-enhanced MR angiography was rarely performed in subjects, although MR angiography or CT angiography was performed on nearly all subjects. Evaluation for coagulopathy was performed in patients 50 years of age or in cases in which physicians deemed it appropriate. Studies with long-term follow-up are needed to document recurrent stroke with potentially identifiable cause and to monitor for arterial, cardioembolic, or small-vessel disease. Additionally, the relationship between gene expression prediction of cryptogenic stroke and other features associated with stroke cause require further study, including imaging criteria and features specified in the Causative Classification for Ischemic Stroke and A-S-C-O stroke classification systems. The profiles used to predict the cause of cryptogenic stroke were derived from a relatively small sample size. Although vascular risk factors, sex, race, and ethnicity were not found to be significantly different between groups, further development and evaluation of RNA predictors of stroke cause in larger cohorts is required to ensure adequate representation of a stroke population. Conclusions The high rates of recurrent stroke and mortality in cryptogenic stroke support the need to develop methods to diagnose this large group of patients. Identifying a cause of stroke is critical to implement prevention therapy and reduce stroke disability and mortality. We demonstrate a probable cause of cryptogenic stroke can be predicted based on the gene expression profile in conjunction with a measure of infarct location. Further study of predicted groups is required to determine whether relevant clinical, imaging, or therapeutic differences exist for each group. Acknowledgments We thank the investigators of the Specialized Programs of Translational Research in Acute Stroke (SPOTRIAS) Stroke Network involved in the CLEAR trial for supplying blood samples for analysis. We appreciate the support of the Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, the Genomics and Expression Resource at the MIND Institute, and the University of California at Davis Department of Neurology. Sources of Funding This study was supported by the National Institutes of Health (NS056302, Dr Sharp) and the American Heart Association (Dr Sharp). Dr Jickling receives support from the Canadian Institutes of Health Research and the American Heart Association. None. Disclosures References 1. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org in Acute Stroke Treatment. Stroke. 1993;24: Ionita CC, Xavier AR, Kirmani JF, Dash S, Divani AA, Qureshi AI. What proportion of stroke is not explained by classic risk factors? Prev Cardiol. 2005;8: Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU. Epidemiology of ischemic stroke subtypes according to toast criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke. 2001;32: Jickling GC, Xu H, Stamova B, Ander BP, Zhan X, Tian Y, et al. Signatures of cardioembolic and large-vessel ischemic stroke. Ann Neurol. 2010;68: Jickling GC, Stamova B, Ander BP, Zhan X, Tian Y, Liu D, et al. Profiles of lacunar and nonlacunar stroke. Ann Neurol. 2011;70: Pancioli AM, Broderick J, Brott T, Tomsick T, Khoury J, Bean J, et al. The combined approach to lysis utilizing eptifibatide and rtpa in acute ischemic stroke: the CLEAR stroke trial. Stroke. 2008;39: Jolliffe IT. Principal Component Analysis. New York, NY: Springer; Stollberger C, Finsterer J. Detection of paroxysmal atrial fibrillation and patent foramen ovale in cryptogenic stroke. Eur J Neurol. 2009;16: Elijovich L, Josephson SA, Fung GL, Smith WS. Intermittent atrial fibrillation may account for a large proportion of otherwise cryptogenic stroke: a study of 30-day cardiac event monitors. J Stroke Cerebrovasc Dis. 2009;18: Amarenco P. Underlying pathology of stroke of unknown cause (cryptogenic stroke). Cerebrovasc Dis. 2009;27(suppl 1): Tayal AH, Tian M, Kelly KM, Jones SC, Wright DG, Singh D, et al. Atrial fibrillation detected by mobile cardiac outpatient telemetry in cryptogenic TIA or stroke. Neurology. 2008;71: Alsheikh-Ali AA, Thaler DE, Kent DM. Patent foramen ovale in cryptogenic stroke: incidental or pathogenic? Stroke. 2009;40: Saver JL. Cryptogenic stroke in patients with patent foramen ovale. Curr Atheroscler Rep. 2007;9: Handke M, Harloff A, Olschewski M, Hetzel A, Geibel A. Patent foramen ovale and cryptogenic stroke in older patients. N Engl J Med. 2007;357: Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a meta-analysis of case control studies. Neurology. 2000;55: Cabanes L, Mas JL, Cohen A, Amarenco P, Cabanes PA, Oubary P, et al. Atrial septal aneurysm and patent foramen ovale as risk factors for cryptogenic stroke in patients less than 55 years of age. A study using transesophageal echocardiography. Stroke. 1993;24: Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, et al. Study design of the CLOSURE I trial: a prospective, multicenter, randomized, controlled trial to evaluate the safety and efficacy of the Starflex
6 Jickling et al Cryptogenic Stroke Prediction 2041 septal closure system versus best medical therapy in patients with stroke or transient ischemic attack due to presumed paradoxical embolism through a patent foramen ovale. Stroke. 2010;41: Harloff A, Dudler P, Frydrychowicz A, Strecker C, Stroh AL, Geibel A, et al. Reliability of aortic MRI at 3 Tesla in patients with acute cryptogenic stroke. J Neurol Neurosurg Psychiatry. 2008;79: Kitagawa K. Aortogenic embolism is a possible mechanism of cryptogenic stroke. Ann Neurol. 2004;55: Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Hennerici MG. New approach to stroke subtyping: the A-S-C-O (phenotypic) classification of stroke. Cerebrovasc Dis. 2009;27: Ay H, Benner T, Arsava EM, Furie KL, Singhal AB, Jensen MB, et al. A computerized algorithm for etiologic classification of ischemic stroke: the causative classification of stroke system. Stroke. 2007;38: Homburg PJ, Rozie S, van Gils MJ, van den Bouwhuijsen QJ, Niessen WJ, Dippel DW, et al. Association between carotid artery plaque ulceration and plaque composition evaluated with multidetector ct angiography. Stroke. 2011;42: Bang OY, Lee PH, Joo SY, Lee JS, Joo IS, Huh K. Frequency and mechanisms of stroke recurrence after cryptogenic stroke. Ann Neurol. 2003;54: Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O Fallon WM, Wiebers DO. Ischemic stroke subtypes: a population-based study of functional outcome, survival, and recurrence. Stroke. 2000;31: Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009;360: Rosenberg S, Elashoff MR, Beineke P, Daniels SE, Wingrove JA, Tingley WG, et al. Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients. Ann Intern Med. 2010;153:
True cryptogenic stroke
True cryptogenic stroke Arne Lindgren, MD, PhD Dept of Clinical Sciences Lund, Neurology, Lund University Dept of Neurology and Rehabilitation Medicine Skåne University Hospital Lund, Sweden Disclosures
More informationBiomarkers of Acute Stroke Etiology (BASE) Study Methodology
Transl. Stroke Res. (2017) 8:424 428 DOI 10.1007/s12975-017-0537-3 ORIGINAL ARTICLE Biomarkers of Acute Stroke Etiology (BASE) Study Methodology Edward C. Jauch 1 & Andrew D. Barreto 2 & Joseph P. Broderick
More informationDirect oral anticoagulants for Embolic Strokes of Undetermined Source? George Ntaios University of Thessaly, Larissa/Greece
Direct oral anticoagulants for Embolic Strokes of Undetermined Source? George Ntaios University of Thessaly, Larissa/Greece Disclosures Scholarships: European Stroke Organization; Hellenic Society of Atherosclerosis.
More informationPatent Foramen Ovale and Cryptogenic Stroke in Older Patients
T h e n e w e ng l a nd j o u r na l o f m e dic i n e original article Patent Foramen Ovale and Cryptogenic Stroke in Older Patients Michael Handke, M.D., Andreas Harloff, M.D., Manfred Olschewski, M.Sc.,
More informationCryptogenic Strokes: Evaluation and Management
Cryptogenic Strokes: Evaluation and Management 77 yo man with hypertension and hyperlipidemia developed onset of left hemiparesis and right gaze preference, last seen normal at 10:00 AM Brought to ZSFG
More informationClinical Features and Subtypes of Ischemic Stroke Associated with Peripheral Arterial Disease
Cronicon OPEN ACCESS EC NEUROLOGY Research Article Clinical Features and Subtypes of Ischemic Stroke Associated with Peripheral Arterial Disease Jin Ok Kim, Hyung-IL Kim, Jae Guk Kim, Hanna Choi, Sung-Yeon
More informationSupplementary webappendix
Supplementary webappendix This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Hart RG, Diener H-C, Coutts SB, et al,
More informationGERIATRICS CASE PRESENTATION
GERIATRICS CASE PRESENTATION CASE 79 year old Patient X was admitted to hospital with SOB. He had a hx of sarcoidosis and asbestosis. Home oxygen requirement is 3-3.5litre. He was admitted, given ceftriaxone
More informationNIH Public Access Author Manuscript J Stroke Cerebrovasc Dis. Author manuscript; available in PMC 2008 September 1.
NIH Public Access Author Manuscript Published in final edited form as: J Stroke Cerebrovasc Dis. 2007 ; 16(5): 216 219. Echocardiography in Patients with Symptomatic Intracranial Stenosis Scott E. Kasner,
More informationIncidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study
Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study Linxin Li, Gabriel S Yiin, Olivia C Geraghty, Ursula G
More informationDEBATE: PFO MANAGEMENT TO CLOSE OR NOT TO CLOSE. Matthew Starr, MD Stroke Attending
DEBATE: PFO MANAGEMENT TO CLOSE OR NOT TO CLOSE Matthew Starr, MD Stroke Attending DISCLOSURES None DEBATE Should PFO be closed? * * Sometimes yes THE CASE AGAINST PFO CLOSURE 1. Did the PFO cause the
More informationQualifying and Outcome Strokes in the RESPECT PFO Trial: Additional Evidence of Treatment Effect
Qualifying and Outcome Strokes in the RESPECT PFO Trial: Additional Evidence of Treatment Effect JEFFREY L. SAVER, MD DAVID E. THALER, MD, PHD, RICHARD W. SMALLING, MD, PHD, JOHN D. CARROLL, MD, SCOTT
More informationΘα πρέπει να αναζηηείηαι η παροσζία ζιωπηλής κολπικής μαρμαρσγή ζε αζθενείς με κρσπηογενές εγκεθαλικό επειζόδιο; Ποιά είναι η καλύηερη μέθοδος;
Θα πρέπει να αναζηηείηαι η παροσζία ζιωπηλής κολπικής μαρμαρσγή ζε αζθενείς με κρσπηογενές εγκεθαλικό επειζόδιο; Ποιά είναι η καλύηερη μέθοδος; Νικόλαος Φραγκάκης Λέκηορας Καρδιολογίας, FESC Ιπποκράηειο
More informationHow Can We Properly Manage Patients With Stroke of Undetermined Origin?
How Can We Properly Manage Patients With Stroke of Undetermined Origin? : Spotlight on Embolic Stroke of Undetermined Source (ESUS) MI SUN OH Department of Neurology, Hallym University Scared Heart Hospital,
More informationEmergently? Michigan Institute for Neurological Disorders. Garden City Hospital, Garden City, Michigan
Why Should TIA be Treated Emergently? Anne M. Pawlak, D.O. F.A.C.N. Michigan Institute for Neurological Disorders Director Neurology Residency Program, Garden City Hospital, Garden City, Michigan According
More informationPermanent foramen ovale: when to close?
Permanent foramen ovale: when to close? Pierre Amarenco INSERM U-698 and Denis Diderot University - Paris VII Department of Neurology and Stroke Center Bichat hospital, Paris, France PFO - Pathology TEE
More informationNon-commercial use only
Italian Journal of Medicine 2016; volume 10:202-206 Embolic stroke of undetermined source: a retrospective analysis from an Italian Stroke Unit Marco Masina, 1 Annalena Cicognani, 1 Carla Lofiego, 2 Simona
More informationPFO Management update
PFO Management update May 12, 2017 Peter Casterella, MD Swedish Heart and Vascular 1 PFO Update 2017: Objectives Review recently released late outcomes of RESPECT trial and subsequent FDA approval of PFO
More information[(PHY-3a) Initials of MD reviewing films] [(PHY-3b) Initials of 2 nd opinion MD]
2015 PHYSICIAN SIGN-OFF (1) STUDY NO (PHY-1) CASE, PER PHYSICIAN REVIEW 1=yes 2=no [strictly meets case definition] (PHY-1a) CASE, IN PHYSICIAN S OPINION 1=yes 2=no (PHY-2) (PHY-3) [based on all available
More informationPatent Foramen Ovale: Diagnosis and Treatment
Patent Foramen Ovale: Diagnosis and Treatment Anthony DeMaria Judy and Jack White Chair in Cardiology University of California, San Diego At one time or another a Grantee, Sponsored Speaker or Ad-hoc Consultant
More informationCryptogenic Stroke: What Don t We Know. Siddharth Sehgal, MD Medical Director, TMH Stroke Center Tallahassee Memorial Healthcare
Cryptogenic Stroke: What Don t We Know Siddharth Sehgal, MD Medical Director, TMH Stroke Center Tallahassee Memorial Healthcare Financial Disclosures None Objectives Principles of diagnostic evaluation
More informationCryptogenic Stroke: The role of silent Atrial Fibrillation
Cryptogenic Stroke: The role of silent Atrial Fibrillation PD Dr. med. Martin A. Ritter Westfälische Wilhelms-Universität Münster Germany ritterm@uni-muenster.de 1 Turin, 25.10.2014 Agenda 1. What is a
More informationNeurological Features and Mechanisms of Acute Bilateral Cerebellar Infarction
Neurological Features and Mechanisms of Acute Bilateral Cerebellar Infarction Ji-Man Hong, M.D., Sang Geon Shin, M.D., Jang-Sung Kim, M.D., Oh-Young Bang, M.D., In-Soo Joo, M.D., Kyoon-Huh, M.D. Department
More informationPatent Foramen Ovale and Cryptogenic Stroke: Do We Finally Have Closure? Christopher Streib, MD, MS
Patent Foramen Ovale and Cryptogenic Stroke: Do We Finally Have Closure? Christopher Streib, MD, MS 11-8-18 Outline 1. Background 2. Anatomy of patent foramen ovale (PFO) 3. Relationship between PFO and
More informationBlood Pressure Reduction Among Acute Stroke Patients A Randomized Controlled Clinical Trial
Blood Pressure Reduction Among Acute Stroke Patients A Randomized Controlled Clinical Trial Jiang He, Yonghong Zhang, Tan Xu, Weijun Tong, Shaoyan Zhang, Chung-Shiuan Chen, Qi Zhao, Jing Chen for CATIS
More informationPrevious studies of patients enrolled in carotid stenosis
Causes and Severity of Ischemic Stroke in Patients With Symptomatic Intracranial Arterial Stenosis Bolanle M. Famakin, MD; Marc I. Chimowitz, MBChB; Michael J. Lynn, MS; Barney J. Stern, MD; Mary G. George,
More informationPFO closure group total no. PFO closure group no. of males
Suppl Table. Characteristics of the five trials included in this meta-analysis. Trial name Device used for Definition of medical Primary Endpoint group total no. group no. of males group age (yrs) group
More informationThe Epidemiology of Stroke and Vascular Risk Factors in Cognitive Aging
The Epidemiology of Stroke and Vascular Risk Factors in Cognitive Aging REBECCA F. GOTTESMAN, MD PHD ASSOCIATE PROFESSOR OF NEUROLOGY AND EPIDEMIOLOGY JOHNS HOPKINS UNIVERSITY OCTOBER 20, 2014 Outline
More informationRahul Jhaveri, M.D. The Heart Group of Lancaster General Health
Rahul Jhaveri, M.D. The Heart Group of Lancaster General Health INTRODUCTION Three recently published randomized controlled trials in The New England Journal of Medicine provide new information about closure
More informationIschemic Stroke in Critically Ill Patients with Malignancy
Ischemic Stroke in Critically Ill Patients with Malignancy Jeong-Am Ryu 1, Oh Young Bang 2, Daesang Lee 1, Jinkyeong Park 1, Jeong Hoon Yang 1, Gee Young Suh 1, Joongbum Cho 1, Chi Ryang Chung 1, Chi-Min
More informationSubtyping of Ischemic Stroke Based on Vascular Imaging: Analysis of 1,167 Acute, Consecutive Patients
Journal of Clinical Neurology / Volume 2 / December, 26 Original Articles Subtyping of Ischemic Stroke Based on Vascular Imaging: Analysis of 1,167 Acute, Consecutive Patients Jin T. Kim, M.D., Sung H.
More informationSupplementary Online Content
Supplementary Online Content Inohara T, Xian Y, Liang L, et al. Association of intracerebral hemorrhage among patients taking non vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital
More informationCVA Updates Karen Greenberg, DO, FACOEP. Director Neurologic Emergency Department Crozer Chester Medical Center
CVA Updates 2018 Karen Greenberg, DO, FACOEP Director Neurologic Emergency Department Crozer Chester Medical Center Disclosure I have the following financial relationship with the manufacturer of any commercial
More informationClinical Study Cardioembolic but Not Other Stroke Subtypes Predict Mortality Independent of Stroke Severity at Presentation
SAGE-Hindawi Access to Research Stroke Research and Treatment Volume 2011, Article ID 281496, 5 pages doi:10.4061/2011/281496 Clinical Study Cardioembolic but Not Other Stroke Subtypes Predict Mortality
More informationI, (Issam Moussa) DO NOT have a financial interest/arrangement t/ t or affiliation with one or more organizations that could be perceived as a real
PFO Closure: Where We Are Going to after CLOSURE I Study? Issam D. Moussa, MD Professor of Medicine Chair, Division of Cardiovascular Diseases Mayo Clinic Jacksonville, Florida Disclosure Statement of
More informationAPPENDIX A NORTH AMERICAN SYMPTOMATIC CAROTID ENDARTERECTOMY TRIAL
APPENDIX A Primary Findings From Selected Recent National Institute of Neurological Disorders and Stroke-Sponsored Clinical Trials That Have shaped Modern Stroke Prevention Philip B. Gorelick 178 NORTH
More informationIndex. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Acute ischemic stroke TOAST classification of, 270 Acute myocardial infarction (AMI) cardioembolic stroke following, 207 208 noncardioembolic
More informationPercutaneous closure of a patent foramen ovale after cryptogenic stroke
Neth Heart J (2018) 26:5 12 https://doi.org/10.1007/s12471-017-1063-3 POINT OF VIEW Percutaneous closure of a patent foramen ovale after cryptogenic stroke R. J. R. Snijder 1 M.J.Suttorp 1 J.M.tenBerg
More informationCritical Review Form Therapy
Critical Review Form Therapy A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects, Lancet-Neurology 2007; 6: 953-960 Objectives: To evaluate the effect of
More informationPATENT FORAMEN OVALE: UPDATE IN MANAGEMENT OF RECURRENT STROKE KATRINE ZHIROFF, MD, FACC, FSCAI LOS ANGELES CARDIOLOGY ASSOCIATES
PATENT FORAMEN OVALE: UPDATE IN MANAGEMENT OF RECURRENT STROKE KATRINE ZHIROFF, MD, FACC, FSCAI LOS ANGELES CARDIOLOGY ASSOCIATES OBJECTIVES Review social burden and epidemiology of stroke Gender disparities
More informationRedgrave JN, Coutts SB, Schulz UG et al. Systematic review of associations between the presence of acute ischemic lesions on
6. Imaging in TIA 6.1 What type of brain imaging should be used in suspected TIA? 6.2 Which patients with suspected TIA should be referred for urgent brain imaging? Evidence Tables IMAG1: After TIA/minor
More informationCHAPTER 5. Symptomatic and Asymptomatic Retinal Embolism Have Different Mechanisms
CHAPTER 5 Symptomatic and Asymptomatic Retinal Embolism Have Different Mechanisms Christine A.C. Wijman, Joao A. Gomes, Michael R. Winter, Behrooz Koleini, Ippolit C.A. Matjucha, Val E. Pochay, Viken L.
More informationREVEAL AF IN YOUR CRYPTOGENIC STROKE PATIENTS
REVEAL AF IN YOUR CRYPTOGENIC STROKE PATIENTS Reveal LINQ TM Insertable Cardiac Monitoring System Are You Looking Long Enough? ONE-THIRD OF ISCHEMIC STROKES ARE CRYPTOGENIC (UNEXPLAINED) 1-6 HOW DO YOU
More informationSpeakers. 2015, American Heart Association 1
Speakers Lee Schwamm, MD, FAHA Executive Vice Chairman of Neurology, Massachusetts General Hospital Director, Stroke Service and Medical Director, MGH TeleHealth, Massachusetts General Hospital Director,
More informationStroke patients have higher mortality than sex- matched
Long- Term Mortality in Patients With Stroke of Undetermined Etiology Hyo Suk Nam, MD, PhD; Hyeon Chang Kim, MD, PhD; Young Dae Kim, MD; Hye Sun Lee, MS; Jinkwon Kim, MD; Dong Hyun Lee, MD; Ji Hoe Heo,
More informationTherapy for Acute Stroke. Systems of Care for TIA
Therapy for Acute Stroke and Systems of Care for TIA Gregory W. Albers, MD Coyote Foundation Professor of Neurology and Neurological Sciences Director, Stanford Stroke Center Stanford University Medical
More informationCT and MR Imaging in Young Stroke Patients
CT and MR Imaging in Young Stroke Patients Ashfaq A. Razzaq,Behram A. Khan,Shahid Baig ( Department of Neurology, Aga Khan University Hospital, Karachi. ) Abstract Pages with reference to book, From 66
More informationMichael Horowitz, MD Pittsburgh, PA
Michael Horowitz, MD Pittsburgh, PA Introduction Cervical Artery Dissection occurs by a rupture within the arterial wall leading to an intra-mural Hematoma. A possible consequence is an acute occlusion
More informationEAE RECOMMENDATIONS FOR TRANSESOPHAGEAL ECHO. Cardiac Sources of Embolism. Luigi P. Badano, MD, FESC
EAE RECOMMENDATIONS FOR TRANSESOPHAGEAL ECHO. Cardiac Sources of Embolism Luigi P. Badano, MD, FESC Background Stroke is the 3 cause of death in several industrial countries; Embolism accounts for 15-30%
More informationEven though it was first proposed as a cause of stroke in
Is Patent Foramen Ovale a Modifiable Risk Factor for Stroke Recurrence? David M. Kent, MD, MS; David E. Thaler, MD, PhD Abstract Although the prevalence of a patent foramen ovale (PFO) in the general population
More informationWHI Form Report of Cardiovascular Outcome Ver (For items 1-11, each question specifies mark one or mark all that apply.
WHI Form - Report of Cardiovascular Outcome Ver. 6. COMMENTS To be completed by Physician Adjudicator Date Completed: - - (M/D/Y) Adjudicator Code: OMB# 095-044 Exp: 4/06 -Affix label here- Clinical Center/ID:
More informationPERCUTANEOUS CLOSURE OF PATENT FORAMEN OVALE AND ATRIAL SEPTAL DEFECT: STATE OF THE ART AND A CRITICAL APPRAISAL
PERCUTANEOUS CLOSURE OF PATENT FORAMEN OVALE AND ATRIAL SEPTAL DEFECT: STATE OF THE ART AND A CRITICAL APPRAISAL Carmelo Cernigliaro Clinica San Gaudenzio Novara Eco 2D e 3D Eco Transesofageo Large shunt
More informationThe Importance of Middle Cerebral Artery Stenosis In Patients With A Lacunar Infarction In The Carotid Artery Territory
The Importance of Middle Cerebral Artery Stenosis In Patients With A Lacunar Infarction In The Carotid Artery Territory Oh Young Bang, M.D., Jeong Hoon Cho, M.D., Ji Hoe Heo, M.D., Dong Ik Kim, M.D.* Department
More informationAntithrombotic therapy in patients with transient ischemic attack / stroke (acute phase <48h)
Antithrombotic therapy in patients with transient ischemic attack / stroke (acute phase
More informationOpen heart surgery or carotid endarterectomy. Which procedure should be done first?
Open heart surgery or carotid endarterectomy. Which procedure should be done first? Pedro Pinto Sousa 1, Gabriela Teixeira 2, João Gonçalves 2 ; Luís Vouga 1, Rui Almeida 2 ; Pedro Sá Pinto 2 1 Centro
More informationRisk factors for and incidence of subtypes of ischemic stroke
Risk factors for and incidence of subtypes of ischemic stroke Hege Ihle-Hansen, MD a Bente Thommessen, MD, PhD b Torgeir Bruun Wyller, MD, PhD c Knut Engedal, MD, PhD c Brynjar Fure, MD, PhD d a Bærum
More information/ / / / / / Hospital Abstraction: Stroke/TIA. Participant ID: Hospital Code: Multi-Ethnic Study of Atherosclerosis
Multi-Ethnic Study of Atherosclerosis Participant ID: Hospital Code: Hospital Abstraction: Stroke/TIA History and Hospital Record 1. Was the participant hospitalized as an immediate consequence of this
More informationAn Introduc+on to Stroke
An Introduc+on to Stroke Elizabeth Huntoon MS, MD Assistant Professor Department of Physical Medicine and Rehabilita>on Vanderbilt University School of Medicine Defini+on Sudden focal neurologic deficit
More informationThrombolysis in ischaemic stroke in rural North East Thailand by neurologist and non-neurologists
Neurology Asia 2016; 21(4) : 325 331 Thrombolysis in ischaemic stroke in rural North East Thailand by neurologist and non-neurologists 1,2 Kannikar Kongbunkiat MD, 1,2 Narongrit Kasemsap MD, 1,2 Somsak
More informationThree months prognosis of transient ischemic attack (TIA) in Erbil Governorate
Three months prognosis of transient ischemic attack (TIA) in Erbil Governorate Received: 26/12/2012 Accepted: 12/6/2013 Introduction A transient ischemic attack (TIA) is a brief episode of neurological
More informationDoes ABCD 2 Score Below 4 Allow More Time to Evaluate Patients With a Transient Ischemic Attack?
Does Below 4 Allow More Time to Evaluate Patients With a Transient Ischemic Attack? Pierre Amarenco, MD; Julien Labreuche, BS; Philippa C. Lavallée, MD; Elena Meseguer, MD; Lucie Cabrejo, MD; Tarik Slaoui,
More informationThe Impact of Smoking on Acute Ischemic Stroke
Smoking The Impact of Smoking on Acute Ischemic Stroke Wei-Chieh Weng, M.D. Department of Neurology, Chang-Gung Memorial Hospital, Kee-Lung, Taiwan Smoking related mortality Atherosclerotic vascular disease
More informationLuisa Vinciguerra. Ictus recidivanti
Luisa Vinciguerra Ictus recidivanti Recurrent Strokes DEFINITION Population-based studies exclude strokes: - within 28 or 21 days of the incident event - events in the same vascular territory as the original
More informationPatent foramen ovale (PFO) is composed of
PFO Closure for Prevention of Recurrent Cryptogenic Stroke The evidence base is here. BY JOHN F. RHODES, JR, MD Patent foramen ovale (PFO) is composed of overlapping portions of septum primum and septum
More informationCEREBRO VASCULAR ACCIDENTS
CEREBRO VASCULAR S MICHAEL OPONG-KUSI, DO MBA MORTON CLINIC, TULSA, OK, USA 8/9/2012 1 Cerebrovascular Accident Third Leading cause of deaths (USA) 750,000 strokes in USA per year. 150,000 deaths in USA
More informationCLINICAL FEATURES THAT SUPPORT ATHEROSCLEROTIC STROKE 1. cerebral cortical impairment (aphasia, neglect, restricted motor involvement, etc.) or brain stem or cerebellar dysfunction 2. lacunar clinical
More informationHEART AND SOUL STUDY OUTCOME EVENT - MORBIDITY REVIEW FORM
REVIEW DATE REVIEWER'S ID HEART AND SOUL STUDY OUTCOME EVENT - MORBIDITY REVIEW FORM : DISCHARGE DATE: RECORDS FROM: Hospitalization ER Please check all that may apply: Myocardial Infarction Pages 2, 3,
More informationTIA: Updates and Management 2008
TIA: Updates and Management 2008 S. Andrew Josephson, MD Department of Neurology, Neurovascular Division University of California San Francisco Commonly Held TIA Misconceptions TIA is easy to diagnose
More informationFORAME OVALE PERVIO E ICTUS CRIPTOGENETICO: Dimensione del problema. Roberto Mantovan, MD, PhD U.O. Cardiologia Ospedale M.
FORAME OVALE PERVIO E ICTUS CRIPTOGENETICO: Dimensione del problema Roberto Mantovan, MD, PhD U.O. Cardiologia Ospedale M. Bufalini - Cesena FORAME OVALE PERVIO ICTUS CRIPTOGENETICO FORAME OVALE PERVIO
More informationFabien Praz, Andreas Wahl, Sophie Beney, Stephan Windecker, Heinrich P. Mattle*, Bernhard Meier
Procedural Outcome after Percutaneous Closure of Patent Foramen Ovale using the Amplatzer PFO Occluder Without Intra-Procedural Echocardiography in 1,000 Patients Fabien Praz, Andreas Wahl, Sophie Beney,
More informationSixth Annual Intensive Update in Neurology 9/15-16/2016. W Tom Kushner DO Swedish Stroke Clinic Neurohospitalist
W Tom Kushner DO Swedish Stroke Clinic Neurohospitalist 1 One Strategy for cryptogenic stroke: ESUS Positively defined criteria FDA allows clinical trials NOACs have lower risk profile Another strategy
More informationStroke Case Studies. Dr Stuti Joshi Neurology Advanced Trainee Telestroke fellow
Stroke Case Studies Dr Stuti Joshi Neurology Advanced Trainee Telestroke fellow Case 1 64 year old female with dysphasia and right arm weakness 3 hours prior CT head: dense M1 sign. No established ischaemia
More informationAssociation of Hypertension With Stroke Recurrence Depends on Ischemic Stroke Subtype
Association of Hypertension With Stroke Recurrence Depends on Ischemic Stroke Subtype Yilong Wang, MD, PhD*; Jie Xu, MD, PhD*; Xingquan Zhao, MD, PhD; David Wang, DO, FAHA, FAAN; Chunxue Wang, MD, PhD;
More information2017 Cardiovascular Symposium CRYPTOGENIC STROKE: A CARDIOVASCULAR PERSPECTIVE DR. WILLIAM DIXON AND DR. VENKATA BAVAKATI SOUTHERN MEDICAL GROUP, P.A.
CRYPTOGENIC STROKE: 2017 Cardiovascular Symposium A CARDIOVASCULAR PERSPECTIVE DR. WILLIAM DIXON AND DR. VENKATA BAVAKATI SOUTHERN MEDICAL GROUP, P.A. CRYPTOGENIC STROKE CRYPTOGENIC: OF OBSCURE OR UNKNOWN
More informationPractical Considerations in the Early Treatment of Acute Stroke
Practical Considerations in the Early Treatment of Acute Stroke Matthew E. Fink, MD Neurologist-in-Chief Weill Cornell Medical College New York-Presbyterian Hospital mfink@med.cornell.edu Disclosures Consultant
More informationGuiding Secondary Stroke Prevention through Evaluation of Ischemic Stroke Etiology
Guiding Secondary Stroke Prevention through Evaluation of Ischemic Stroke Etiology Ann M. Leonhardt Caprio, MS, RN, ANP-BC Program Coordinator Comprehensive Stroke Center, Strong Memorial Hospital Clinical
More informationTACLS-Chapter-2-Body-Structure.pdf Essential Resources
Stroke Network 1. http://www.strokebestpractices.ca/wp-content/uploads/2016/01/ TACLS-Chapter-2-Body-Structure.pdf Essential Resources Stroke Rehabilitation Unit Orientation Module 1: Pathophysiology of
More informationAdvances in the treatment of posterior cerebral circulation symptomatic disease
Advances in the treatment of posterior cerebral circulation symptomatic disease Athanasios D. Giannoukas MD, MSc(Lond.), PhD(Lond.), FEBVS Professor of Vascular Surgery Faculty of Medicine, School of Health
More informationStarting or Resuming Anticoagulation or Antiplatelet Therapy after ICH: A Neurology Perspective
Starting or Resuming Anticoagulation or Antiplatelet Therapy after ICH: A Neurology Perspective Cathy Sila MD George M Humphrey II Professor and Vice Chair of Neurology Director, Comprehensive Stroke Center
More informationDiabetes mellitus is an accepted independent risk factor for
Lacunar Strokes in Patients With Diabetes Mellitus: Risk Factors, Infarct Location, and Prognosis The Secondary Prevention of Small Subcortical Strokes Study Santiago Palacio, MD; Leslie A. McClure, PhD;
More informationEarly neurological worsening in acute ischaemic stroke patients
Acta Neurol Scand 2016: 133: 25 29 DOI: 10.1111/ane.12418 2015 The Authors. Acta Neurologica Scandinavica Published by John Wiley & Sons Ltd ACTA NEUROLOGICA SCANDINAVICA Early neurological in acute ischaemic
More informationManagement and Investigation of Ischemic Stroke By Etiology
Management and Investigation of Ischemic Stroke By Etiology Andrew M. Demchuk MD FRCPC Director, Calgary Stroke Program Deputy Dept Head, Clinical Neurosciences Heart and Stroke Foundation Chair in Stroke
More informationOpen Access The Addition of MRI to CT Based Stroke and TIA Evaluation Does Not Impact One year Outcomes
Send Orders of Reprints at reprints@benthamscience.net The Open Neurology Journal, 2013, 7, 17-22 17 Open Access The Addition of MRI to CT Based Stroke and TIA Evaluation Does Not Impact One year Outcomes
More informationGame Strategy: High Intensity Statin in Stroke. K.M. Osei MD, MSc Cardiovascular Conference PARMC Feb 24, 2018
Game Strategy: High Intensity Statin in Stroke K.M. Osei MD, MSc Cardiovascular Conference PARMC Feb 24, 2018 No Disclosures Are you Mind Full or Mindful? Objectives 1. Discuss the correlation between
More informationA trial fibrillation (AF) is a common arrhythmia that is
679 PAPER Atrial fibrillation as a predictive factor for severe stroke and early death in 15 831 patients with acute ischaemic stroke K Kimura, K Minematsu, T Yamaguchi, for the Japan Multicenter Stroke
More informationSession : Why do stroke patients need a cardiologist? PREVALENCE OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CEREBRAL INFARCTION
Session : Why do stroke patients need a cardiologist? PREVALENCE OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CEREBRAL INFARCTION The Asymptomatic Myocardial Ischemia in Stroke and Atherosclerotic Disease
More informationIs Stroke a Paradoxical Embolism in Patients with Patent Foramen Ovale?
ORIGINAL ARTICLE Is Stroke a Paradoxical Embolism in Patients with Patent Foramen Ovale? Masahiro YASAKA, Ryoichi OTSUBO, Hiroshi OE and Kazuo MINEMATSU Abstract Objective Purpose was to assess the stroke
More informationEarly Hospitalization of Patients with TIA: A Prospective, Population-based Study
Early Hospitalization of Patients with TIA: A Prospective, Population-based Study Mohamed Al-Khaled, MD, and J urgen Eggers, MD Background: The German Stroke Society (GSS) recommends early hospitalization
More informationFeatures of branch occlusive disease-type intracranial atherosclerotic stroke in young patients
Zhao et al. BMC Neurology (2018) 18:87 https://doi.org/10.1186/s12883-018-1089-1 RESEARCH ARTICLE Open Access Features of branch occlusive disease-type intracranial atherosclerotic stroke in young patients
More informationIn 1982, Fisher 1 described 2 possible arteriolar pathologies
Variation in Risk Factors for Recent Small Subcortical Infarcts With Infarct Size, Shape, and Location Alessandra Del Bene, PhD; Stephen D.J. Makin, MRCP; Fergus N. Doubal, PhD; Domenico Inzitari, MD;
More informationWhat the general cardiologist should know about arrhythmia Stroke prevention in AF" Peter Ammann Kantonsspital St. Gallen
What the general cardiologist should know about arrhythmia Stroke prevention in AF" Peter Ammann Kantonsspital St. Gallen What the cardiologist should know about arrhythmia and stroke are there real low
More informationOpen Access. Original Article
Original Article Early and intermediate prognosis of intravenous thrombolytic therapy in acute ischemic stroke subtypes according to the causative classification of stroke system Ali Pashapour 1, Abolfazl
More informationAntithrombotic Summit Basel 2012 Basel, 26. April Peter T. Buser Klinik Kardiologie Unviersitätsspital Basel
Antithrombotic Summit Basel 2012 Basel, 26. April 2012 Peter T. Buser Klinik Kardiologie Unviersitätsspital Basel Background stroke = third-leading cause of death among adults 1/5 of stroke survivors require
More informationSubclinical AF: Implications of device based episodes
Subclinical AF: Implications of device based episodes Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC Disclosures: Clinical Trials and Consulting: Medtronic, Boston Scientific
More informationThrombolysis-WAKE UP Intra-arterial interventions DEFUSE 3 Haemorrhagic Stroke - TICH 2 Secondary Prevention CROMIS 2 Secondary Prevention NAVIGATE
Thrombolysis-WAKE UP Intra-arterial interventions DEFUSE 3 Haemorrhagic Stroke - TICH 2 Secondary Prevention CROMIS 2 Secondary Prevention NAVIGATE ESUS Progression of haematoma Anticoagulation Large ICH
More informationCommon Codes for ICD-10
Common Codes for ICD-10 Specialty: Cardiology *Always utilize more specific codes first. ABNORMALITIES OF HEART RHYTHM ICD-9-CM Codes: 427.81, 427.89, 785.0, 785.1, 785.3 R00.0 Tachycardia, unspecified
More informationSmall Vessel Stroke. Domenico Inzitari Careggi University Hospital Florence (Italy)
Small Vessel Stroke Domenico Inzitari Careggi University Hospital Florence (Italy) Topics Lacunar stroke The small vessel conundrum Small and large Conclusions Fisher s lacunar syndromes Pure motor hemiparesis
More informationClinical Policy: Transcatheter Closure of Patent Foramen Ovale Reference Number: CP.MP.151
Clinical Policy: Reference Number: CP.MP.151 Effective Date: 12/17 Last Review Date: 12/17 See Important Reminder at the end of this policy for important regulatory and legal information. Coding Implications
More informationWhy Treat Patent Forman Ovale
Why Treat Patent Forman Ovale Clifford J Kavinsky, MD, PHD Professor of Medicine and pediatrics Associate Director, Center for Congenital and Structural Heart Disease Rush University Medical Center Conclusions
More information